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Abstract
Purpose
The purpose was to assess the differences between subcutaneous basal/bolus and sliding scale insulin
protocols in patients admitted with type 2 diabetes on non-critical care units.

Methods
A retrospective review of electronic medical records was conducted on a convenience sample of
inpatients in a central-city teaching hospital.

Results
The findings were that basal/bolus protocols achieved American Diabetes Association glycemic targets
on fasting, mean, and discharge blood glucoses.

Conclusions
This study provided insight into glycemic control and interdisciplinary education needs at this hospital.
Evidence revealed that basal/bolus insulin protocols can achieve glycemic targets.
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Hyperglycemia, or high blood glucose, among hospitalized patients is associated with adverse shortand long-term outcomes such as increased lengths of stay and increased time for healing. In fact, in 1
study,1 the association of hyperglycemia and mortality was greater in patients without a history of
diabetes compared to those with diabetes. A retrospective analysis determined that nearly 25% of
patients admitted with diabetes were hyperglycemic, with a blood glucose > 200 mg/dl (11.1 mmol/l)
upon admission because they were either poorly controlled on their prehospital diabetes regimen, or
they were poorly controlled because of their primary admission diagnosis, which often was related to
infection.2
For the majority of nonacute hospitalized patients with diabetes, pre-meal blood glucose targets
should generally be < 140 mg/dl (7.8 mmol/l), with random blood glucose levels < 180 mg/dl (10.0
mmol/l). Special considerations need to be taken into account, however, for patients with severe
comorbidities and those who are terminally ill when higher glucose targets may be warranted. 3
Subcutaneous insulin therapy is the preferred method of glycemic control on non-critical care units for
patients with diabetes. There are various types of insulin protocols for treating hyperglycemia in the
hospital setting. Treatment options include sliding-scale insulin or basal/bolus insulin therapy.
Hospitalized patients are prone to large variances in blood glucoses. Because of this, effective
treatment is required to maintain satisfactory, safe glucose control. Subcutaneous sliding-scale insulin
has been long-used as routine therapy for treatment of hyperglycemia and involves administering premeal insulin 4-6 times per day, depending on the pre-meal blood glucose.
Although it has been frequently used, there is a lack of evidence supporting the effectiveness of this
practice.4 Sliding-scale insulin usually consists of regular insulin or rapid-acting insulin given alone. This
technique has been shown to be ineffective for the following reasons: the reactive approach can lead
to rapid swings in blood glucose, resulting in hyperglycemia and hypoglycemia, the regimen in place at
admission is likely to be used throughout the hospitalization without appropriate change or titration,
and hyperglycemia is treated after the fact instead of proactively anticipating need. In a retrospective
study, Freedman et al5 proposed that patients with high admission blood glucoses were more likely to
be placed on a sliding scale insulin (SSI) protocol. Freedman also indicated that other patients were
often placed on a sliding scale protocol because it was a method that was passed down from trainee
to trainee as an easy, “auto-pilot” way to treat diabetes in the hospital, a method that would limit the

need for physician intervention. The hazards of sliding-scale insulin use exceed the advantages of
its convenience, and thus prolonged therapy using this insulin as the sole source of treatment is discouraged.6
In the noncritical care setting, scheduled subcutaneous insulin that delivers basal, nutritional (bolus),
and correction (supplemental) doses are preferred because this type of therapy is shown to be more
physiological—ie, more closely matching endogenous basal and bolus insulin secretion.3 However,
SSI is still predominantly used on the study hospitals' medical non-critical care units. Insulin protocols
at this hospital are prescribed by hospitalists, residents, surgeons, internal medicine physicians, family
medicine physicians, and nurse practitioners (NPs)/physician assistants. The orders are implemented
by the staff nurses and are often a source of frustration as they are usually the first caregiver to
recognize that the blood glucose is not being well-controlled.
Diabetes NPs can be consulted to collaborate with staff nurses on a regimen change and patient
education needs. Diabetes NPs can implement best practices as they relate to control of inpatient
hyperglycemia and are key providers to coordinate and provide inpatient diabetes care.

Methods
A retrospective chart review of patients hospitalized with known type 2 diabetes was conducted for
the purpose of quality improvement at a 140-bed, central-city teaching hospital in Milwaukee, WI. The
chart review was specifically performed to study the outcomes that basal bolus vs SSI protocols had on
fasting, mean, and discharge blood glucoses, length of stay (LOS), and episodes of mild/moderate or
severe hypoglycemia. Inclusion criteria included patients age 18-80, admitted to general medical units,
and managed on either basal/bolus or SSI protocols.
Exclusion criteria included patients admitted to critical care units, including intermediate care units, as
well as surgical and obstetrical units. Patients who were found to have undergone surgery, though
admitted initially to a medical unit, were excluded, as well as those who received steroids, oral
diabetes agents, or intravenous insulin at any time during their stay. Patients who were hospitalized for
fewer than 3 days were also excluded.
The institutional review boards at the study hospital and Marquette University approved the quality
improvement study. Clinical information services at the study hospital conducted a search using ICD 9
diagnosis codes of 250.0 and 250.02 and the aforementioned inclusion and exclusion criteria for
patients admitted between January 1, 2009, and January 1, 2012. Lists were provided by clinical
information services that identified patients by their medical record number, discharge date, LOS, age,
sex, ethnicity, admission diagnosis, and nursing unit.
A review of the electronic record for each patient who met the inclusion criteria was conducted in the
sequence in which they appeared. Subjects were de-identified. The blood glucose data included
glucose levels tested before each meal and at bedtime. The goal of insulin therapy was to maintain
fasting and pre-meal blood sugars < 140 mg/dl (7.78 mmol/l), and overall < 180 mg/dl (10.0 mmol/l)
while avoiding hypoglycemia (no lower than 70 mg/dl or 3.89 mmol/l).3 The primary goal was to
determine differences between the 2 groups of subjects based on the type of insulin protocol.

Sample
A power analysis was conducted using the G*Power calculator (Buchner, Erdfelder, and Faul,
Duesseldorf Germany) for an independent t-test. It was concluded that to achieve significance, a
sample of 128 patients with type 2 diabetes was required. The sample size was evenly divided between
patients placed on basal/bolus protocols and those placed on SSI protocols. The demographic variable
data collected for the sample included age, ethnicity, sex, admission blood glucose, admission
diagnosis, hemoglobin A1C, serum hemoglobin, serum creatinine, and white blood cell count. These
particular variables were chosen because they can have an impact on the blood glucose and help
explain hyper and hypoglycemia.
The independent t-test was used for variables with continuous data, and the Mann Whitney U test was
used for variables with categorical data. The age of the sample did not differ significantly: sliding-scale
group (SS) age mean = 65.2 ± standard deviation = 9.6; basal-bolus group (BB) age 63.3 ± 11.8. Ethnicity
of the sample revealed largely an African American population for both groups because of the hospital
location, with smaller populations of white and Hispanic patients.
The sex of the sample did not differ on the large number of women vs men. The admission glucoses
were similar (SS 210.3 ± 149.5; BB 210.3 ± 138.2), and hemoglobin A1c values did not differ as both
groups were admitted in fairly poor control (SS 8.3 ± 1.6; BB 8.2 ± 2.03). The white cell count did not
reveal a large mean for infections being a major reason for admissions (SS 8.5 ± 3.3; BB 9.2 ± 4.2), and
hemoglobin values did not indicate that anemia was significantly low, leading to an inaccurate
Hemoglobin A1c value (SS 10.9 ± 2.3; BB 11.5 ± 2.8).
Finally, though the creatinine value of the groups did not show a statistically significant difference (P =
.395), the means indicated that a large portion of the SS group had high creatinines as compared to
the BB group (SS 2.9 ± 3.3; BB 1.7 ± 1.6). This may be an interesting future study as another reason for
the safety of using a BB regimen (Table 1).
Table 1. Description of Sample/Demographic Variables
Variable

Sliding Scale Protocol
Mean & SD (n = 64)
65.2 ± 9.6
59 AA, 2 W, 3 H
40 F, 24 M

Basal Bolus Protocol
Mean & SD (n = 64)
63.3 ± 11.8
53 AA, 6 W, 5 H
38 F, 26 M

Age (years)
Ethnicity
Sex
(female/male)
Admission
210.3 ± 149.5
210.3 ± 138.2
glucose
Hemoglobin A1C
8.3 ± 1.6
8.2 ± 2.03
(%)
White blood cell
8.5 ± 3.3
9.2 ± 4.2
count
Hemoglobin
10.9 ± 2.3
11.5 ± 2.8
Creatinine
2.9 ± 3.3
1.7 ± 1.6
AA = African American; W = white; H = Hispanic.

P value: Ind. ttest/MannWhitney U
.273
.244
.333
.774
.860
.190
.526
.395

P = < 0.05.

Statistical Analysis
Statistical analysis was performed using the SPSS software package (IBM Corporation, Armonk, NY).7
Independent t-tests were used to analyze continuous variables. Distributions on scores of several
dependent variables were not normally distributed, and thus equality of variances was not assumed.
Because of the possibility of a 30% type 1 error with multiple t tests, the confidence interval was set at
70%.

Results
The means and standard deviations for variables associated with the hypotheses are reported in
Table 2 where the P value demonstrated those variables that showed significance. The first hypothesis
(H1) was that there would be a significant difference between BB and SSI protocols on fasting blood
glucose, mean blood glucose, and discharge blood glucose. This hypothesis was supported with fasting
blood glucose values: SS 201.4 ± 33.7; BB 135.5 ± 29.9, mean blood glucose values: SS 225 ± 37.5; BB
149 ± 23.1, and discharge blood glucose values: SS 244.3 ± 68.2; BB 128.6 ± 27.3 (Table 2).
Table 2. Results
Variables

Fasting
blood
glucose
Mean
blood
glucose
Discharge
blood
glucose
Mild/mod.
hypo
Severe
hypo
Length of
stay (days)

Sliding
Scale
Protocol
Mean & SD
(n = 64)

Basal Bolus
Protocol
Mean & SD
(n = 64)

Sig. (2tailed)

t

Std. Error
Difference

70%
Confidence
Interval

201.4 ±
33.7

135.5 ±
29.9

.000

11.711 5.62633

Lower
60.03521

Upper
71.74604

225 ± 37.5

149 ± 23.1

.000

13.813 5.50101

70.25461

81.71414

244.3 ±
68.2

128.6 ±
27.3

.000

12.610 9.17937

106.17619

125.32381

.6250 ±
1.29
.1719 ± .46

.7031 ± 1.3

.730

−.345

.22623

−.31357

.15732

.1406 ± .59

.737

.336

.09296

−.06550

.12800

4.6 ± 1.9

4.8 ± 2.8

.195

−.473

.42950

−.65012

.24387

The second hypothesis (H2) was that there would be a significant difference in length of stay for BB
and SSI protocols. This hypothesis was not supported as values included: SS 4.6 ± 1.9; BB 4.8 ± 2.8
(Table 2).

The third hypothesis (H3) was that there would be a significant difference in the incidence of
mild/moderate and severe hypoglycemic episodes for BB and SSI protocols. This hypothesis was not
supported with values for mild/moderate hypoglycemia (SS .6250 ± 1.29; BB .7031 ± 1.3) and for
severe hypoglycemic episodes (SS .1719 ±.46; BB .1406 ±.59) (Table 2).

Discussion
Overall, this study was consistent with other research on BB regimens as far as improvements seen in
fasting blood glucose, mean blood glucose, and discharge blood glucose.2, 5, 8, 9, 10, 13, 14 The results for
H1 are consistent with Freedman et al5, in which patients on SSI had a mean blood glucose > 270 mg/dl
(15.0 mmol/l). The mean blood glucose in this study for patients on the SSI protocol was 224 mg/dl
(12.4 mmol/l). In Umpierrez et al11, the mean for SSprotocol patients was 193 mg/dl (10.7 mmol/l), and
the mean fasting blood glucose was 165 mg/dl (9.17 mmol/l). The fasting blood glucose in this study
for SS protocol patients was 201 mg/dl (11.17 mmol/l). These results are all higher than the pre-meal
glucose target of < 140 mg/dl (7.78 mmol/l) and random glucose target of < 180 mg/dl (10.0 mmol/l) as
set by the American Diabetes Association, suggesting that SSI protocols do not meet the standards for
achieving good glycemic control in this study.3
The analysis of hypoglycemia revealed that there were no statistically significant results regarding
episodes of mild/moderate (< 70 mg/dl or 3.9 mmol/l) or severe hypoglycemia (< 50 mg/dl or 2.8
mmol/l). There were a slightly larger number of episodes of mild/moderate hypoglycemia with BB
therapy than with SS therapy and slightly more episodes of severe hypoglycemia with SS therapy as
compared to BB therapy. This is consistent with other studies as far as SS being a potentially dangerous
therapy as compared to BB therapy.5, 10, 15
The analysis of the LOS data was also not statistically significant between BB and SS groups. The mean
LOS were similar for both groups, and compared to Umpierrez et al11, this study actually had shorter
LOS.
The analysis of the other variables concluded that there were no statistically significant differences in
age, ethnicity, sex, white blood cell count, hemoglobin, creatinine, A1C, or admission blood glucose for
either group.
The knowledge and expertise in diabetes of the advanced practice nurse, along with a specialty
flowsheet within the electronic medical record, provided consistency and reliability in how the data
were collected. Finally, the sample consisted of patients from medical units with a prior diagnosis of
type 2 diabetes, so this was a fairly homogeneous convenience sample from 1 hospital.

Limitations
One limitation of this study included its retrospective design. The retrospective electronic medical
record does not allow the researcher to inquire why decisions were made. For example, glucose
readings may have been taken shortly after the patient had begun eating and the insulin dose may not
have been timed appropriately with meals. This hospital allowed “on-demand meals,” and thus
patients could order meals when they wanted and would receive and start eating the meal without the
staff RN's knowledge. The meal-time insulin would then be given late. Since this study was done, a

system was put into place whereby a sign on the door alerted the kitchen staff to contact the patient's
RN before giving the patient a tray.
Generalizability of the results was limited because of the sample being from noncritical care units and
because the sample was obtained from a single central-city hospital. Thus, though the study is
replicable, it may not be representative of diabetes care in other settings.
Another limitation of this study is that it did not track how many patients were admitted because they
had infections compared to how many were admitted only for poorly controlled diabetes.

Conclusion
The results of this project provide direction for improving the care of hospitalized patients with
hyperglycemia in this facility. The evidence that BB insulin protocols provide improved glycemic control
over SS protocols in this facility needs to be presented to all caregivers.
NPs specializing in diabetes are key members of the inpatient care team for the translation of research
related to evidence-based diabetes practice. In addition to providing this evidence, NPs specializing
in diabetes should be included on committees that write institutional guidelines on when and how to
initiate and change/adjust insulin therapy. This topic should be part of every orientation for 1st year
residents and part of the yearly competency skills for RNs.
Protocols via the electronic medical record should also be designed to allow staff nurses to implement
interventions independently such as basal/bolus dos-ing based on a patient's weight. Inpatient
diabetes update sessions would also benefit other prescribers such as hospitalists and external
providers who still admit their own patients. The advanced practice diabetes educator can be
instrumental in coordinating future studies to assess progress with the use evidence-based practice
diabetes protocols, as well as studies that assess the rate of 30-day readmissions for uncontrolled
hyperglycemia since this is now being scrutinized regarding reimbursement. 12
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